- Jounce Therapeutics (NASDAQ:JNCE) has initiated patient enrollment in INNATE Phase 1 clinical study of its lead macrophage program JTX-8064 as a monotherapy and in combination with either JTX-4014, its internal PD-1 inhibitor, or pembrolizumab in patients with advanced solid tumors.
- “Expansion cohorts in INNATE will address multiple different patient populations, including PD-(NYSE:L)1 inhibitor naïve patients with both PD-(L)1 inhibitor sensitive and resistant tumor types, and PD-(L)1 inhibitor experienced patients whose tumors were resistant to PD-(L)1 inhibitors," said Beth Trehu, M.D., Chief Medical Officer.
- INNATE will also assess pharmacodynamic and potential predictive biomarkers to guide future development, aligning with Jounce’s philosophy of developing the right immunotherapies for the right patients.
- Shares up 4% premarket.